RASBURNAT 1.5MG ING

About

Rasburnat 1.5mg Injection, containing Rasburicase, is an enzyme medication used for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis syndrome (TLS) and subsequent hyperuricemia. TLS is a potentially life-threatening metabolic complication that can occur rapidly following the initiation of chemotherapy, leading to high levels of uric acid, potassium, and phosphate in the blood, which can cause acute kidney injury and cardiac arrhythmias.

Rasburicase works by catalyzing the enzymatic oxidation of uric acid into allantoin, a more soluble and easily excretable compound. This rapid conversion helps to prevent and treat hyperuricemia, thereby reducing the risk of renal failure and other complications associated with TLS. It is administered intravenously and its effects are typically seen quickly. Due to the risk of hypersensitivity reactions and methemoglobinemia, particularly in patients with G6PD deficiency, careful monitoring is required during and after administration.

Uses

• Prevention of hyperuricemia in tumor lysis syndrome
• Treatment of existing hyperuricemia in TLS
• For patients with leukemia, lymphoma, and solid tumors
• Reducing the risk of acute kidney injury from high uric acid

Directions For Use

Administered intravenously by a healthcare professional. Dosage and duration are determined by your doctor based on your condition.

Benefits

• Rapidly lowers uric acid levels
• Prevents and treats tumor lysis syndrome
• Reduces risk of acute kidney injury
• Effective in high-risk cancer patients
• Improves patient safety during chemotherapy
• Well-established efficacy in managing hyperuricemia

Side Effects

• Nausea
• Vomiting
• Diarrhea
• Fever
• Headache
• Abdominal pain
• Hypersensitivity reactions
• Anaphylaxis
• Methemoglobinemia
• Hemolysis (in G6PD deficient patients)
• Peripheral edema
• Rash

Safety Measures

• Alcohol - No specific interaction with alcohol is known, but it's generally advisable to avoid alcohol during cancer treatment.
• Pregnancy - Rasburnat is not recommended during pregnancy unless the potential benefits outweigh the risks. Consult your doctor.
• Breastfeeding - It is unknown if Rasburicase passes into breast milk. Breastfeeding is generally not advised during treatment.
• Liver - Use with caution in patients with severe liver impairment, although no specific dose adjustments are typically required.
• Kidney - Rasburnat is used to prevent kidney injury from hyperuricemia. No specific precautions for pre-existing kidney conditions are usually needed, but monitor renal function.
• Lung - Rare cases of acute respiratory distress syndrome have been reported. Monitor for any new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.